Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection (post-viral hyposmia) No FDA-approved drug therapy available for this increasingly …
Trending at Lumira Ventures
Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia)
There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition. Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has commenced enrollment in the Phase …
Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia)
Currently no FDA-approved therapy for this serious condition Initiation of Phase 2 clinical trial expected to occur in Q2 2023 Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S. Food and …
Cyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors
Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, today announced that it has appointed biopharmaceutical industry veteran John Kollins to its board of directors. Kollins is currently President and Chief Executive …
Lumira co-leads $12.8 Million raise in Cyrano Therapeutics
Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. …